No abstract available.
Antibodies* ; Hepatitis Viruses* ; Hepatitis*

No abstract available.
Hepatitis A Antibodies* ; Hepatitis* ; Immunoglobulin M*

No abstract available.
Hepacivirus* ; Hepatitis C Antibodies* ; Hepatitis C* ; Hepatitis*

No abstract available.
Antibodies* ; Hepatitis B Surface Antigens* ; Hepatitis* ; Prevalence*

According to the reports, the prevalence of anti-HCV is about 1%. In past, the results of the prevalence of HBs Ag & HBs Ab in the patients of Hansen's disease were reported. But we don't know about that of anti-HCV. So we study about the prevalence of serum anti-HCV of 60 patients & PALS of Hansen's disease. And we test about Alk. Phosp., ALT, AST, Gtlc HBs Ag & HBs Ab. 1. The prevalence of anti-HCV is 8.33%. It is higher than past reports(about 1-2%). 2. The prevalence of HBs Ag is 3.4% & that of HBs Ab is 36.3%. 3. Because of the high prevalence of anti-HCV in the patients of Hansen's disease & PALS, we think that more studies are need about it.
Hepacivirus* ; Hepatitis C Antibodies* ; Hepatitis C* ; Hepatitis* ; Humans ; Leprosy ; Prevalence

No abstract available.
Hepacivirus* ; Hepatitis C Antibodies* ; Hepatitis C* ; Hepatitis* ; Prevalence*

BACKGROUND/AIMS: The aim of this study was to evaluate the seroconversion rate of a hepatitis A virus (HAV) vaccination in patients with hepatitis B virus (HBV)-related chronic liver disease (CLD). METHODS: Analyses were conducted using clinical records from 94 patients with chronic HBV infection who were seronegative for IgG anti-HAV antibodies between September 2008 and June 2009. Two doses of an HAV vaccine were administered 24 weeks apart. A third vaccine dose was administered only for patients seronegative for anti-HAV antibodies at week 48. RESULTS: The seroconversion rate of anti-HAV following the two-dose vaccination was 86.17%. The seroconversion rate of anti-HAV was not significantly different according to age or status of liver disease. The rate was higher in female than in male patients. A third HAV vaccine dose was administered to 13 patients seronegative for anti-HAV after the two-dose regimen, and 84.62% of these patients showed seroconversion at week 72. CONCLUSIONS: HAV vaccination is effective in most Korean patients with HBV-related CLD, and it might be necessary to evaluate three-dose vaccination approach for non-responders to the conventional regimen to maximize the success of an HAV vaccination program.
Antibodies ; Female ; Hepatitis ; Hepatitis A ; Hepatitis A Antibodies ; Hepatitis A virus ; Hepatitis B ; Hepatitis B virus ; Hepatitis B, Chronic ; Humans ; Immunoglobulin G ; Korea ; Liver ; Liver Diseases ; Male ; Vaccination

No abstract available.
Antibodies* ; Female ; Hepatitis B* ; Hepatitis* ; Humans ; Pregnant Women*

No abstract available.
Antibodies* ; Hepacivirus* ; Hepatitis C* ; Hepatitis* ; Humans ; Prevalence* ; Renal Dialysis*

The rate of HBsAg carriers among blood donors at at Thua Thien Hue province during 5 years (1997 - 2001) is relative high, with 13.57% on average. At the same time, the incidence of HCV infection is lower than other areas (with mean 0.64%). The rate of HBsAg carrier is higher in rural than in Hue city (14.72% vs. 12.27%). The young adults in precincts have higher HBsAg incidence than in other groups.
Blood Donors ; Hepatitis B Surface Antigens ; Hepatitis C Antibodies